152 related articles for article (PubMed ID: 27149479)
21. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
Sun A
Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
Shan D; Cheng S; Ma Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
[TBL] [Abstract][Full Text] [Related]
23. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract][Full Text] [Related]
24. Standardized uptake value
Jin B; Wen X; Tian H; Guo H; Hao M; Wu J; Li X; Ren Y; Wang X; Ren X
Cancer Med; 2024 Apr; 13(7):e6961. PubMed ID: 38549459
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of serum DJ-1 in lung adenocarcinoma.
Wang L; Wei L; Miao S; Zhang W
PeerJ; 2024; 12():e16845. PubMed ID: 38304191
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic potential of protein serum biomarkers for distinguishing small and non-small cell lung cancer in patients with suspicious lung lesions.
Sua LF; Serrano-Gomez SJ; Nuñez M; Amezquita-Dussan MA; Fernández-Trujillo L
Biomarkers; 2024 May; ():1-13. PubMed ID: 38804910
[TBL] [Abstract][Full Text] [Related]
27. Use of tumor markers in distinguishing lung adenocarcinoma-associated malignant pleural effusion from tuberculous pleural effusion.
Ai L; Wang W; Li J; Ye T; Li Y
Am J Med Sci; 2024 Apr; ():. PubMed ID: 38583522
[TBL] [Abstract][Full Text] [Related]
28. Serum CYFRA21-1 and SCC-Ag levels in women during pregnancy and their diagnostic value for cervical cancer.
Zhang Q; Wang Z; Tang H; Zhang B; Yue C; Gao J; Ying C
Cancer Treat Res Commun; 2024; 38():100786. PubMed ID: 38198984
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
[TBL] [Abstract][Full Text] [Related]
30. Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma
Pan J; Zhuang W; Xia Y; Huang Z; Zheng Y; Wang X; Huang Y
PeerJ; 2024; 12():e17141. PubMed ID: 38529301
[TBL] [Abstract][Full Text] [Related]
31. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract][Full Text] [Related]
32. A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer.
Yu Z; Lu H; Si H; Liu S; Li X; Gao C; Cui L; Li C; Yang X; Yao X
PLoS One; 2015; 10(5):e0125517. PubMed ID: 25996920
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and racial differences in pterygium: a cross-sectional study in Han and Uygur adults in Xinjiang, China.
Chen T; Ding L; Shan G; Ke L; Ma J; Zhong Y
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1109-17. PubMed ID: 25626966
[TBL] [Abstract][Full Text] [Related]
34. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
35. Distribution of
Abudukeremu M; Ayoufu A; Tuerhong A; Paizula X; Ou JH
Open Life Sci; 2024; 19(1):20220728. PubMed ID: 38681733
[TBL] [Abstract][Full Text] [Related]
36. Serum Markers CA125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of Lung Cancer in High-Risk Populations.
Li G; Zhang H; Zhang L; Liu H; Li S; Wang Y; Deng X
Biomed Res Int; 2022; 2022():1394042. PubMed ID: 36299704
[TBL] [Abstract][Full Text] [Related]
37. New Insights on Old Biomarkers Involved in Tumor Microenvironment Changes and Their Diagnostic Relevance in Non-Small Cell Lung Carcinoma.
Wadowska K; Błasiak P; Rzechonek A; Bil-Lula I; Śliwińska-Mossoń M
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439874
[TBL] [Abstract][Full Text] [Related]
38. Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.
Qin WW; Wang P; Ding C; Peng F
J Med Biochem; 2023 Oct; 42(4):607-615. PubMed ID: 38084245
[TBL] [Abstract][Full Text] [Related]
39. Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
Nakao M; Kinoshita R; Kuriyama M; Kiyotoshi H; Sugihara M; Takeda N; Ohtakara K; Muramatsu H
Anticancer Res; 2024 Feb; 44(2):845-851. PubMed ID: 38307561
[TBL] [Abstract][Full Text] [Related]
40. Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
Zhou D; Zhai X; Zhang R
PLoS One; 2023; 18(9):e0291461. PubMed ID: 37699023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
